257 related articles for article (PubMed ID: 30269117)
41. Multimodality Image-Guided Cryoablation for Inoperable Tumor-Induced Osteomalacia.
Tella SH; Amalou H; Wood BJ; Chang R; Chen CC; Robinson C; Millwood M; Guthrie LC; Xu S; Levy E; Krishnasamy V; Gafni RI; Collins MT
J Bone Miner Res; 2017 Nov; 32(11):2248-2256. PubMed ID: 28718983
[TBL] [Abstract][Full Text] [Related]
42. Definitive surgical treatment of osteomalacia induced by skull base tumor and determination of the half-life of serum fibroblast growth factor 23.
Hana T; Tanaka S; Nakatomi H; Shojima M; Fukumoto S; Ikemura M; Saito N
Endocr J; 2017 Oct; 64(10):1033-1039. PubMed ID: 28768937
[TBL] [Abstract][Full Text] [Related]
43. Sinonasal hemangiopericytoma caused hypophosphatemic osteomalacia: A case report.
Li J; Huang Y; Yang F; Zhang Q; Chen D; Wang Q
Medicine (Baltimore); 2018 Dec; 97(52):e13849. PubMed ID: 30593185
[TBL] [Abstract][Full Text] [Related]
44. Diagnostic Modalities for FGF23-Producing Tumors in Patients with Tumor-Induced Osteomalacia.
Fukumoto S
Endocrinol Metab (Seoul); 2014 Jun; 29(2):136-43. PubMed ID: 25031885
[TBL] [Abstract][Full Text] [Related]
45. [Osteomalacia due to phosphate deficiency caused by a tumor. Focus on FGF23 in physiology and clinic].
Westerberg PA; Linde T; Ljunggren O
Lakartidningen; 2012 Aug 8-21; 109(32-33):1414-6. PubMed ID: 22953430
[No Abstract] [Full Text] [Related]
46. Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis.
Goldsweig BK; Carpenter TO
Curr Osteoporos Rep; 2015 Apr; 13(2):88-97. PubMed ID: 25620749
[TBL] [Abstract][Full Text] [Related]
47. [Clinical aspect of recent progress in phosphate metabolism. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23)].
Endo I
Clin Calcium; 2009 Jun; 19(6):815-20. PubMed ID: 19483276
[TBL] [Abstract][Full Text] [Related]
48. [Updates on rickets and osteomalacia: anti-FGF23 antibody, a new therapeutic approach for hypophosphatemic rickets/osteomalacia].
Shimada T
Clin Calcium; 2013 Oct; 23(10):1469-75. PubMed ID: 24076645
[TBL] [Abstract][Full Text] [Related]
49. Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy.
Ovejero D; El-Maouche D; Brillante BA; Khosravi A; Gafni RI; Collins MT
J Bone Miner Res; 2017 Aug; 32(8):1667-1671. PubMed ID: 28459498
[TBL] [Abstract][Full Text] [Related]
50. [Clinical features, diagnostics and treatment of FGF23 secreting tumors: series of 40 clinical cases].
Gronskaia SA; Belaya ZE; Rozhinskaya LY; Melnichenko GA; Dubovitskaya TA; Mamedova EO; Rodionova SS; Buklemishev YV; Pigarova EA; Degtyarev MV; Babaeva DM; Vladimirova VP; Tarbaeva NV; Serzhenko SS; Grigoriev AY; Dzeranova LK; Karpenko VY; Karasev AL; Fedotov RN; Uliyanova IN; Toroptsova NV; Lesnyak OM; Mokrysheva NG; Dedov II
Probl Endokrinol (Mosk); 2023 Nov; 69(5):25-38. PubMed ID: 37968949
[TBL] [Abstract][Full Text] [Related]
51. Patients with FGF23-related hypophosphatemic rickets/osteomalacia do not present with left ventricular hypertrophy.
Takashi Y; Kinoshita Y; Hori M; Ito N; Taguchi M; Fukumoto S
Endocr Res; 2017 May; 42(2):132-137. PubMed ID: 27754732
[TBL] [Abstract][Full Text] [Related]
52. Tumor-induced osteomalacia: benign tumor recurrence after two surgical resections at two different medical institutions.
Yasuda S; Wada S; Kono S; Miyajima T; Oda H; Katayama S; Awata T
Endocr Pract; 2013; 19(4):e97-101. PubMed ID: 23512396
[TBL] [Abstract][Full Text] [Related]
53. Molecular Imaging in Diagnosis of Tumor-induced Osteomalacia.
Yang M; Doshi KB; Roarke MC; Nguyen BD
Curr Probl Diagn Radiol; 2019; 48(4):379-386. PubMed ID: 30078476
[TBL] [Abstract][Full Text] [Related]
54. Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia.
Imanishi Y; Ito N; Rhee Y; Takeuchi Y; Shin CS; Takahashi Y; Onuma H; Kojima M; Kanematsu M; Kanda H; Seino Y; Fukumoto S
J Bone Miner Res; 2021 Feb; 36(2):262-270. PubMed ID: 32967046
[TBL] [Abstract][Full Text] [Related]
55. Levels and dynamic changes of serum fibroblast growth factor 23 in hypophosphatemic rickets/osteomalacia.
Xia WB; Jiang Y; Li M; Xing XP; Wang O; Hu YY; Zhang HB; Liu HC; Meng XW; Zhou XY
Chin Med J (Engl); 2010 May; 123(9):1158-62. PubMed ID: 20529556
[TBL] [Abstract][Full Text] [Related]
56. [Fibroblast growth factor 23--a phosphate regulating hormone].
Beck-Nielsen SS; Pedersen SM; Kassem M; Rasmussen LM
Ugeskr Laeger; 2010 May; 172(20):1521-7. PubMed ID: 20483099
[TBL] [Abstract][Full Text] [Related]
57. Challenges in the management of tumor-induced osteomalacia (TIO).
Brandi ML; Clunie GPR; Houillier P; Jan de Beur SM; Minisola S; Oheim R; Seefried L
Bone; 2021 Nov; 152():116064. PubMed ID: 34147708
[TBL] [Abstract][Full Text] [Related]
58. Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition.
Mak MP; da Costa e Silva VT; Martin RM; Lerario AM; Yu L; Hoff PM; de Castro G
Support Care Cancer; 2012 Sep; 20(9):2195-7. PubMed ID: 22552356
[TBL] [Abstract][Full Text] [Related]
59. [Fibroblast growth factor (FGF) 23 works as a phosphate-regulating hormone and is involved in the pathogenesis of several disorders of phosphate metabolism].
Fukumoto S
Rinsho Byori; 2007 Jun; 55(6):555-9. PubMed ID: 17657990
[TBL] [Abstract][Full Text] [Related]
60. [FGF23-related hypophosphatemic rickets/osteomalacia].
Ito N; Fukumoto S
Clin Calcium; 2007 Oct; 17(10):1514-20. PubMed ID: 17906402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
